Low Testosterone Tied to Higher Cancer Mortality, Study Finds

When researchers dove into the hormone profiles of over 26,000 men, they uncovered a surprising pattern: those with especially low testosterone faced an 18% higher chance of succumbing to cancer later in life. It’s a finding that could reshape how doctors think about early‑risk screening.

The data came from the Androgens In Men Study (AIMS), a collaboration spanning Australia, the United States and Europe and led by Professor Bu Yeap at the University of Western Australia. By pairing blood‑test hormone measurements taken years ago with cancer diagnoses and mortality records that followed, the team could glimpse how hormone levels might foreshadow future disease.

What stood out was a clear threshold. Men whose testosterone dipped below roughly 8.6 nmol/L – well under the 10‑30 nmol/L range typical for younger, healthy males – began to see their cancer‑related risk climb. It wasn’t just a subtle uptick; the increase persisted even after the researchers adjusted for age, body‑mass index, diabetes and other health variables.

But the story isn’t the same for every cancer. Prostate cancer, long suspected to be driven by testosterone, showed no connection to men’s natural testosterone levels at all. Instead, lower concentrations of sex‑hormone‑binding globulin (SHBG) and luteinizing hormone (LH) were the hormonal culprits linked to higher prostate‑cancer incidence.

"We wanted to know whether the concentration of these hormones in the blood was related to the risk of men being diagnosed with, or dying from, cancer into the future," Professor Yeap explained. "What we saw was that if a man had low testosterone – in the lowest one‑fifth compared to the highest one‑fifth – his subsequent risk of dying from cancer was higher."

These findings raise a practical question: should men get their testosterone checked as part of routine health exams? While the study stops short of proving causation, it does suggest that unusually low testosterone could serve as an early warning sign, prompting doctors to look more closely at a patient’s overall health.

Importantly, the researchers caution against leaping straight to testosterone therapy as a preventive measure. "We haven’t got any evidence yet that actually giving men testosterone will reduce that risk," Professor Yeap noted. The takeaway is more about investigation than supplementation.

So, if a routine blood test reveals testosterone well beneath the 8.6 nmol/L mark, the prudent next step is a thorough medical check‑up. That could uncover hidden conditions—like metabolic disorders or chronic inflammation—that might be driving the hormonal dip and, in turn, the heightened cancer risk.

In short, while low testosterone isn’t a death sentence, it appears to be a useful biomarker. As researchers continue to untangle the complex web of hormones and disease, men and their doctors now have another piece of the puzzle when it comes to long‑term health planning.